2023 Fiscal Year Final Research Report
Actin Dynamics-associated Induction of Osteoblast Differentiation in Umbilical Cord-derived Mesenchymal Stem Cells
| Project/Area Number |
20K10010
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 57040:Regenerative dentistry and dental engineering-related
|
|---|
| Research Institution | Nagoya University (2023)
Nagasaki University (2020-2022) |
|---|
Principal Investigator |
Iwatake Mayumi 名古屋大学, 未来社会創造機構, 特任准教授 (40624614)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
住田 吉慶 長崎大学, 医歯薬学総合研究科(歯学系), 教授 (50456654)
長村 登紀子 東京大学, 医科学研究所, 准教授 (70240736)
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 臍帯由来間葉系幹細胞 / 骨再生 / 骨芽細胞分化誘導 |
|---|
| Outline of Final Research Achievements |
Recently, mesenchymal stem cells (MSCs) have been proposed as a new bone regeneration method that is minimally invasive and highly effective, but there are many challenges to overcome. MSCs derived from umbilical cord, which can be harvested noninvasively, have been reported to have high proliferative activity and the ability to differentiate into bone tissue, but it takes time to induce differentiation and their differentiation potential is lower than that of MSCs derived from other tissues. Therefore, we developed a novel culture method for umbilical cord MSCs that induces accelerated differentiation and examined its optimization, and found that bone differentiation can be promoted by intervening in the dynamic changes of actin.
This differentiation induction method suggested the possibility of creating osteoblast preparations for transplantation by a novel culture technique applying actin polymerization regulating factors.
|
| Free Research Field |
骨再生
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では将来の標準治療となり得る方法の開発を目指しており、従来多く用いられている骨髄由来MSCによる骨再生法に比べて、侵襲が少なく、治療期間の短縮や、感染などのリスクも減らすことができるところが長所である。また自家細胞製品は完全オーダーメイド製品であるため高コストになりがちであるが、臍帯MSCは現在、バンクへのストックが進められているため、製造段階のスケールを大きくすることで製造コストを抑えられると予想される。よって将来的には安価で効果の高い安全な骨再生医療が実現すると考えている。
|
